197 related articles for article (PubMed ID: 28415690)
1. Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.
Cheng L; Liu YY; Lu PH; Peng Y; Yuan Q; Gu XS; Jin Y; Chen MB; Bai XM
Oncotarget; 2017 Apr; 8(17):28385-28394. PubMed ID: 28415690
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
3. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
4. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
Allen JE; Krigsfeld G; Mayes PA; Patel L; Dicker DT; Patel AS; Dolloff NG; Messaris E; Scata KA; Wang W; Zhou JY; Wu GS; El-Deiry WS
Sci Transl Med; 2013 Feb; 5(171):171ra17. PubMed ID: 23390247
[TBL] [Abstract][Full Text] [Related]
5. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.
Chen MB; Zhou ZT; Yang L; Wei MX; Tang M; Ruan TY; Xu JY; Zhou XZ; Chen G; Lu PH
Oncotarget; 2016 Mar; 7(13):17047-59. PubMed ID: 26933997
[TBL] [Abstract][Full Text] [Related]
6. Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells.
Song Y; Lu M; Qiu H; Yin J; Luo K; Zhang Z; Jia X; Zheng G; Liu H; He Z
Exp Mol Pathol; 2018 Aug; 105(1):57-62. PubMed ID: 29856982
[TBL] [Abstract][Full Text] [Related]
7. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.
Zhang Q; Wang H; Ran L; Zhang Z; Jiang R
Biochem Biophys Res Commun; 2016 Aug; 476(4):260-266. PubMed ID: 27233611
[TBL] [Abstract][Full Text] [Related]
8. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Wang JG; Zheng XX; Zeng GY; Zhou YJ; Yuan H
Oncol Rep; 2014 Jan; 31(1):488-96. PubMed ID: 24247909
[TBL] [Abstract][Full Text] [Related]
9. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
10. Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.
Zhen YF; Li ST; Zhu YR; Wang XD; Zhou XZ; Zhu LQ
Oncotarget; 2016 Nov; 7(48):79417-79427. PubMed ID: 27765904
[TBL] [Abstract][Full Text] [Related]
11. MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4.
Xu C; Shi L; Chen W; Fang P; Li J; Jin L; Pan Z; Pan C
Oncotarget; 2017 Jun; 8(26):41921-41931. PubMed ID: 28410209
[TBL] [Abstract][Full Text] [Related]
12. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
13. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
[TBL] [Abstract][Full Text] [Related]
14. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells.
Lee JY; Jung KH; Morgan MJ; Kang YR; Lee HS; Koo GB; Hong SS; Kwon SW; Kim YS
Mol Cancer Ther; 2013 Mar; 12(3):274-85. PubMed ID: 23053497
[TBL] [Abstract][Full Text] [Related]
16. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx.
Moon DO; Kang CH; Kang SH; Choi YH; Hyun JW; Chang WY; Kang HK; Koh YS; Maeng YH; Kim YR; Kim GY
Toxicol Appl Pharmacol; 2012 Feb; 259(1):87-95. PubMed ID: 22200406
[TBL] [Abstract][Full Text] [Related]
18. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma.
Chen XP; He SQ; Wang HP; Zhao YZ; Zhang WG
World J Gastroenterol; 2003 Nov; 9(11):2433-40. PubMed ID: 14606071
[TBL] [Abstract][Full Text] [Related]
19. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway.
Wu F; Chen WJ; Yan L; Tan GQ; Li WT; Zhu XJ; Ge XC; Liu JW; Wang BL
Cancer Med; 2016 Feb; 5(2):370-85. PubMed ID: 26714930
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
